What is Onllan D?
Onllan D is a medicine that increases the movements or contractions of the stomach and bowel. Onllan D is also used to treat nausea and vomiting caused by other drugs used to treat Parkinson's Disease.
Onllan D is to be given only by or under the immediate supervision of your doctor.
Onllan D indications
Dyspeptic symptom complex often associated with delayed gastric emptying, gastroesophageal reflux disease (GERD) or esophagitis: Epigastric sense of fullness, feeling of abdominal distention, upper abdominal pain, flatulence (gassiness), eructation (belching), and heartburn.
Short-term treatment of nausea and vomiting of various origins including functional, organic, infectious, diabetic origin, or induced by radiotherapy or medicine therapy. (It is not considered suitable for chronic nausea and vomiting, nor for the routine prophylaxis of postoperative vomiting.)
Treatment of nausea and vomiting induced by dopamine agonists ie, L-dopa and bromocriptine used in Parkinson's disease.
Onllan D may also be given as needed, together with paracetamol for the symptomatic treatment of nausea and vomiting associated with migraine.
Uses of Onllan D in details
Onllan D is used to treat vomiting or nausea caused due to indigestion, diseases or drugs. It is also used to relieve fullness of stomach, belching and heavy bloating, gas and heartburn for a longer period up to 2 weeks.
Onllan D description
Onllan D is a synthetic anticoagulant and an indanedione derivative. It prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K mediated gamma-carboxylation of precursor proteins.
Onllan D dosage
It is recommended to take oral Onllan D before meals. If taken after meals, absorption of the drug is somewhat delayed.
Adults and Adolescents >12 years and weighing ≥35 kg: Tablets: One to two 10-mg tablet 3-4 times/day, with a maximum daily dose of 8 tablets (80 mg).
Oral Suspension:
10-20 mL (of oral susp containing Onllan D 1 mg/mL) 3-4 times/day, with a maximum daily dose of 80 mL.Infants and Children: 0.25-0.5 mg/kg 3-4 times/day with a maximum daily dose of 2.4 mg/kg (but do not exceed 80 mg/day).
Tablets are unsuitable for use in children weighing <35 kg.
Oral Suspension:
0.25-0.5 mg/kg 3-4 times/day with a maximum dose of 2.4 mg/kg (not exceeding 80 mL).Onllan D interactions
The concomitant administration of Onllan D with phenothiazines, butyrophenones and rauwolfia alkaloids may induce the endocrine disturbances or extrapyramidal disorders. If necessary, monitored carefully and administered cautiously.
Should be administered cautiously in patients receiving digitalis preparations.
The concomitant administration of Onllan D with anticholinergic agents may compromise the beneficial effects of Onllan D because of depressing the promoting action of gastrointestinal motility.
Theologically, Onllan D may have an effect on the absorption of oral preparations, especially slow-releasing or enteric-coated preparations because of increasing gastric motility. But in patients stabilized with digoxin or acetaminophen, the concomitant administration of Onllan D had no effect on plasma concentration of these drugs.
It is not reported that Onllan D enhances the effect of neuroleptics.
Onllan D inhibits peripheral adverse reactions eg, dyspepsia, nausea, vomiting, induced by dopamine agonist (eg, bromocriptine, levodopa), but has no effect on central nervous system.
As the concomitant administration of Onllan D with antacids or acid secretion inhibitors lowers biologic activity of Onllan D, these drugs should not be used together.
The actions of Onllan D on gastrointestinal function may be antagonised by antimuscarinics and opioid analgesics.
Onllan D side effects
See also:
What are the possible side effects of Onllan D?
Clinical Trial Data: The safety of Onllan D was evaluated in 1221 patients with gastroparesis, dyspepsia, gastro-oesophageal reflux disorder (GERD) or other related conditions in 45 clinical trials included in the safety database. All patients were ≥15 years and received at least 1 dose of oral Onllan D (Onllan D base). Slightly fewer than one-half (553/1221) of patients were diabetic. The median total daily dose was 80 mg (range 10-160 mg), with 230 patients receiving a dose >80 mg. Median duration of exposure was 56 days (range 1-2248 days).
Adverse drug reactions (ADRs) reported by ≥1% of patients treated with oral Onllan D in these 45 clinical trials (n=1221) are the following: Psychiatric Disorders: Depression (2.5%), anxiety (1.6%), decreased libido/loss of libido (1.5%).
Nervous System Disorders: Headache (5.6%), somnolence (2.5%), akathisia (1%).
Gastrointestinal Disorders: Diarrhoea (5.2%).
Skin and Subcutaneous Tissue Disorders: Rash (2.8%), pruritus (1.7%).
Reproductive System and Breast Disorders: Breast enlargement/gynaecomastia (5.3%), breast tenderness (4.4%), galactorrhoea (3.3%), amenorrhoea (2.9%), breast pain (2.3%), irregular menstruation (2%), lactation disorder (1.6%).
General Disorders and Administration Site Conditions: Asthenia (1.9%).
ADRs that occurred in <1% of Onllan D-treated patients in the 45 clinical trials (n=1221) are the following: Immune System Disorders: Hypersensitivity (0.2%).
Skin and Subcutaneous Disorders: Urticaria (0.7%).
Reproductive System and Breast Disorders: Breast discharge (0.8%), breast swelling (0.5%).
Dry mouth has been reported with over-the-counter use of Onllan D.
Post-Marketing: In addition to the adverse effects reported during clinical studies and previously mentioned, the following adverse drug reactions provided the frequencies according to the following convention: Very common (≥1/10), common (≥1/100 and <1/10); uncommon (≥1/1000 and <1/100); rare (≥1/10,000 and <1/1000); very rare (<1/10,000, including isolated reports).
The following ADRs are presented by frequency category based on spontaneous reporting rates: Immune System Disorders: Very Rare: Anaphylactic reactions (including anaphylactic shock).
Psychiatric Disorders: Very Rare: Agitation, nervousness.
Nervous System Disorders: Very Rare: Extrapyramidal disorder, convulsion.
Cardiac Disorders: Very Rare: Sudden cardiac death*, serious ventricular arrhythmias*.
Skin and Subcutaneous Tissue Disorders: Very Rare: Angioedema.
Renal and Urinary Disorders: Very Rare: Urinary retention.
Investigations: Very Rare: Abnormal liver function test; increased blood prolactin.
Note: *Based on epidemiology data (as follows).
As the hypophysis is outside the blood-brain barrier, Onllan D may cause an increase in prolactin levels. In rare cases, this hyperprolactinaemia may lead to neuro-endocrinological side effects eg, galactorrhoea, gynaecomastia and amenorrhoea.
Extrapyramidal disorder occurs primarily in neonates and infants.
Other central nervous system-related effects of convulsion and agitation are also reported primarily in infants and children.
An increase in the risk of serious ventricular arrhythmias and sudden cardiac death has been reported in some epidemiology studies. Due to the limitations of these data, risk factors and the exact frequency of these adverse reactions could not be defined.
Onllan D contraindications
Hypersensitivity to Onllan D or any ingredient of Onllan D.
If patients are taking oral ketoconazole, fluconazole, voriconazole, erythromycin, clarithromycin, telithromycin, amiodarone, selective serotonin reuptake inhibitors, HIV protease inhibitors, calcium antagonists which can increase plasma concentrations of Onllan D, leading to a prolonged QTc interval. These medicines can increase plasma concentrations of Onllan D leading to a prolonged QTc interval. Patients with long QT syndrome develop a very fast heart rhythm disturbance leading to a sudden loss of consciousness.
Gastrointestinal hemorrhage (bleeding), obstruction, perforation or conditions where gastrointestinal stimulation or movements may be dangerous.
Prolactin-releasing pituitary tumor (prolactinoma).
Active ingredient matches for Onllan D:
| Unit description / dosage (Manufacturer) | Price, USD |
| Onllan D 30+10 Capsule | $ 0.07 |
List of Onllan D substitutes (brand and generic names): | |
| Onilan D | |
| Onilan D 30+10 Tablet (Knox Life Sciences) | $ 0.07 |
| Onto D | |
| Onto D 20+10 Capsule (Aronex Life Sciences Pvt. Ltd.) | $ 0.05 |
| OP D | |
| OP D 20+10 Capsule (Ultimedix) | $ 0.06 |
| OP Zole D | |
| OP Zole D 20+10 Capsule (United Lifecare Pvt Ltd) | $ 0.05 |
| Opar DM | |
| Opar DM 20+10 Capsule (Paras Laboratories Limited) | $ 0.05 |
| OPAR DM 10MG/20MG CAPSULE 1 strip / 10 capsules each (Paras Laboratories Limited) | $ 0.58 |
| Opar DM Capsule (Paras Laboratories Limited) | $ 0.06 |
| Opar DM Tab | |
| Opar DM Tab 20+10 Tablet (Paras Laboratories Limited) | $ 0.12 |
| Opel D | |
| Opel D 20+10 Capsule (Medopharm) | $ 0.06 |
| Operidone (Vietnam) | |
| Operidone 100 mg x 1 Bottle 30 mL | |
| Operidone 100 mg x 1 Bottle 60 mL | |
| Opizol D | |
| Opizol D 20+10 Capsule (Grampus Laboratories) | $ 0.06 |
| OPL D | |
| OPL D 20+10 Capsule (Winsmed Pharmaceuticals Pvt Ltd) | $ 0.05 |
| Opra D | |
| Opra D 20+10 Tablet (BRD Medilabs) | $ 0.05 |
| Opratab DM | |
| Opratab DM 20+10 Tablet (Ravenbhel Pharmaceuticals (P) Ltd) | $ 0.04 |
| OPRATAB DM 10 MG/20 MG TABLET 1 strip / 10 tablets each (Ravenbhel Pharmaceuticals (P) Ltd) | $ 0.54 |
| Opratab DM 10 mg/20 mg Tablet (Ravenbhel Pharmaceuticals (P) Ltd) | $ 0.05 |
| Oprazole D | |
| Oprazole D 20+10 Tablet (Pramukh Swami Pharma Ltd.) | $ 0.05 |
| OPZ D | |
| OPZ D 20+10 Tablet (Excare Laboratories) | $ 0.05 |
| OPZ D 10MG/20MG TABLET 1 strip / 10 tablets each (Excare Laboratories) | $ 0.54 |
| Opz D Tablet (Excare Laboratories) | $ 0.05 |
| Oraz D | |
| Oraz D 20+10 Capsule (Osper Pharmaceutics Pvt. Ltd.) | $ 0.04 |
| Orbazol DSR | |
| Orbazol DSR 20+30 Capsule (Oirpil Biotech) | $ 0.07 |
| Oricid D | |
| Oricid D 20+10 Capsule (Orison Pharmaceuticals) | $ 0.05 |
| Orid D | |
| Orid D 20+10 Capsule (Welkind Pharma) | $ 0.07 |
| Orik DM | |
| Orik DM 20+10 Capsule (Lanark Laboratories Pvt Ltd) | $ 0.05 |
| Oriner (Vietnam) | |
| Oriner 10 mg x 3 Blister x 10 Tablet | |
| Oriner 10 mg x 6 Blister x 10 Tablet | |
| Oriner 10 mg x 10 Blister x 10 Tablet | |
| Oriner 10 mg x 25 Blister x 10 Tablet | |
| Oriner 10 mg x 50 Blister x 10 Tablet | |
| Oriner 10 mg x 1 Bottle 100 Tablet | |
| Oriner 10 mg x 1 Bottle 200 Tablet | |
| Oriner 10 mg x 1 Bottle 500 Tablet | |
| Orio D | |
| Orio D 20+10 Tablet (Glosun Pharmaceuticals (P) Ltd.) | $ 0.06 |
| Oroperidys (Belgium, Bulgaria, Estonia, Greece, Latvia, Lithuania, Malta, Slovakia) | |
| Tablet, Dispersible; Oral; Domperidone 10 mg (Pierre fabre medicament) | |
| Oropéridys (France) | |
| Tablet, Dispersible; Oral; Domperidone 10 mg | |
| Oroperidys 10mg (Luxembourg) | |
| Oshzol D | |
| Oshzol D 20+10 Tablet (Mystico Rose Pharma) | $ 0.06 |
| Ospicid D | |
| Ospicid D 20+10 Tablet (Auspi Medicaments) | $ 0.06 |
| Ossum D | |
| Ossum D 20+10 Capsule (Zenacts Pharma (Kaizen Drugs (P) Ltd)) | $ 0.07 |
| Osteocid D | |
| Osteocid D 20+30 Capsule (Wanbury Ltd.) | $ 0.10 |
See 2682 substitutes for Onllan D | |
References
- PubChem. "domperidone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "domperidone". http://www.drugbank.ca/drugs/DB01184 (accessed September 17, 2018).
- DTP/NCI. "domperidone: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Onllan D are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Onllan D. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
